Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Top Page
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$16.50
▲(0.86% Upside)
Action:ReiteratedDate:03/25/26
The score is held down primarily by weak financial performance (revenue collapse to zero, ongoing losses, and sustained cash burn), which increases reliance on external funding. The latest earnings call provides a meaningful offset with clear clinical timelines and an expected cash runway into 2028, but the outcome remains highly binary around the Phase III readout. Technicals are mildly negative near-term, and valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Pivotal Trial Enrollment & Timeline
Completing Phase III enrollment and setting a clear Q3 2026 readout converts ongoing development risk into a defined clinical milestone. This enables focused capital allocation, a discrete regulatory path and the potential to transition rapidly to NDA preparation and commercialization planning if results are positive, reducing execution ambiguity over the medium term.
Negative Factors
Revenue Collapse & Operating Losses
The abrupt revenue decline to zero and large recent net losses show the company lacks ongoing commercial cash flow and operating leverage. Over the medium term, this forces reliance on external financing and makes corporate value highly contingent on clinical outcomes, increasing dilution and financial vulnerability if development timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Trial Enrollment & Timeline
Completing Phase III enrollment and setting a clear Q3 2026 readout converts ongoing development risk into a defined clinical milestone. This enables focused capital allocation, a discrete regulatory path and the potential to transition rapidly to NDA preparation and commercialization planning if results are positive, reducing execution ambiguity over the medium term.
Read all positive factors
Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.81B
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue Growth-100.34%
EPS Growth52.85%
CountryUS
Employees123
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding110,536,940
10 Day Avg. Volume1,182,112
30 Day Avg. Volume1,099,602
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.12
Enterprise Value/Ebitda-7.97
Forecast
1Y Price Target
$23.86Price Target Upside45.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.35
Revenue Forecast (FY)N/A
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a d...
How the Company Makes Money
null...
Amylyx Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive progress: pivotal trial enrollment complete, clear timelines (top-line Q3 2026), expanded pipeline (AMX318 nomination), AMX114 Fast Track and favorable safety, and a cash runway into 2028. Near-term cautions include a reduced cash balance versus the prior quarter, a $4M milestone payment, modeled placebo/powering conservatism, and the binary risk around the Phase III readout and subsequent regulatory/ commercialization steps. Overall, the positives — clinical progress, pipeline expansion, cost discipline, and adequate cash runway — outweigh the near-term operational and clinical uncertainties.Positive Updates
Phase III LUCIDITY Initiation and Enrollment Complete
Completed recruitment for the pivotal Phase III LUCIDITY trial of Avexatide (90 mg daily) in post-bariatric hypoglycemia (PBH); expect to randomize and dose remaining eligible participants this month and deliver top-line data in Q3 2026.
Negative Updates
Near-Term Cash Movement and Upcoming Milestone Spend
Cash balance decreased from $344M to $317M quarter-over-quarter (≈7.8% decline). Management disclosed a $4.0 million milestone payment to Gubra recognized in Q1 2026 R&D, which will increase near-term spend.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase III LUCIDITY Initiation and Enrollment Complete
Completed recruitment for the pivotal Phase III LUCIDITY trial of Avexatide (90 mg daily) in post-bariatric hypoglycemia (PBH); expect to randomize and dose remaining eligible participants this month and deliver top-line data in Q3 2026.
Read all positive updates
Company Guidance
Amylyx reiterated a clear, metric-driven plan: deliver top‑line LUCIDITY Phase III data in Q3 2026 (trial enrollment is complete and final randomizations/dosing expected this month), testing Avexatide 90 mg once daily on the FDA‑agreed Week‑16 composite of level‑2 and level‑3 hypoglycemic events (program informed by five prior trials—Phase 2 showed a 64% least‑squares mean reduction vs baseline, p=0.0031—and the Phase III was conservatively powered assuming up to a 50% placebo effect and a 35% effect size vs placebo); prepare NDA sections and regulatory readiness to move rapidly after readout with the goal of a potential 2027 commercial launch if approved; and continue portfolio development (AMX318 nominated in January with an IND target of 2027; AMX114 Fast Track with cohort‑two enrollment completing this month and biomarker data expected H1). Financially, the company ended Q4 with $317M in cash and marketable securities (down from $344M in Q3), providing an anticipated cash runway into 2028 to fund milestones, while Q4 operating expenses were $36.6M (−8% YoY) with R&D $21.2M, SG&A $15.4M, stock‑based compensation $6.4M, and a noted $4M milestone payment to Gubra to be reflected in Q1 2026 R&D.Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 87.37M | 380.79M | 22.23M | 0.00 |
| Gross Profit | -525.00K | 45.22M | 355.35M | 19.24M | 0.00 |
| EBITDA | -144.16M | -290.98M | 39.89M | -200.85M | -82.64M |
| Net Income | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
Balance Sheet | |||||
| Total Assets | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M |
| Cash, Cash Equivalents and Short-Term Investments | 316.98M | 176.50M | 371.36M | 346.94M | 96.12M |
| Total Debt | 5.96M | 1.98M | 4.24M | 6.28M | 0.00 |
| Total Liabilities | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M |
| Stockholders Equity | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M |
Cash Flow | |||||
| Free Cash Flow | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
| Operating Cash Flow | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Investing Cash Flow | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Financing Cash Flow | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
Amylyx Pharmaceuticals Inc Technical Analysis
Positive
16.36
Price Trends
14.45
Positive
13.97
Positive
12.34
Positive
Market Momentum
0.61
Negative
61.32
Neutral
91.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 16.36 is above the 20-day moving average (MA) of 14.55, above the 50-day MA of 14.45, and above the 200-day MA of 12.34, indicating a bullish trend. The MACD of 0.61 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 91.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 89 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amylyx Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.67B | 13.56 | 19.84% | ― | 21.13% | 50.86% | |
70 Outperform | $2.40B | 6.20 | -76.45% | ― | 45.38% | 92.85% | |
66 Neutral | $4.75B | -9.59 | ― | ― | -42.64% | -39.78% | |
57 Neutral | $1.71B | -7.95 | -70.76% | ― | ― | -20.08% | |
52 Neutral | $1.81B | ― | -57.52% | ― | -100.34% | 52.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.38B | -1.64 | -688.89% | ― | ― | 18.76% |
* Healthcare Sector Average
AMLX
Amylyx Pharmaceuticals Inc
16.36
12.46
319.49%
BCRX
BioCryst
9.56
2.52
35.80%
DNTH
Dianthus Therapeutics
89.77
71.06
379.80%
HRMY
Harmony Biosciences Holdings
28.89
-0.64
-2.17%
PHVS
Pharvaris
26.63
14.01
111.01%
BHVN
Biohaven Ltd.
9.17
-9.34
-50.46%
Amylyx Pharmaceuticals Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
Positive
Mar 24, 2026
On March 24, 2026, Amylyx Pharmaceuticals updated its corporate presentation to reflect several clinical development milestones across its rare disease pipeline. The company reported completion of enrollment in the Phase 3 LUCIDITY trial of avexit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.